Pliant Therapeutics, Inc. PLRX
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is an oncology drug developer. Its lead program, PLN-101095, is in Phase 1 for solid tumors resistant to immune checkpoint inhibitors (NSCLC, ccRCC, high-TMB tumors) in combination with pembrolizumab. Its next catalyst on record is Integrin-targeted delivery platform: Additional platform detail and initial treatment indications (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Integrin-targeted delivery platform — Additional platform detail and initial treatment indications (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PLN-101095 (FORTIFY Phase 1b indication expansion) | NSCLC, clear cell RCC, high tumor mutational burden tumors | small molecule | Phase 1 |
| Integrin-targeted siRNA delivery platform | skeletal muscle, adipocytes, renal cells (indications TBD) | RNA (siRNA/ASO/mRNA) | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.